Document is current
Any future updates will be listed below
-
Authors
Thavaneswaran, Subotheni
Lin, Frank
Espinoza, David
Grady, John
Kok, Peey-Sei
Chinchen, Sarah
Pavlakis, Nick
Andelkovic, Vladimir
Charakidis, Michail
Craft, Paul
Brown, Michael
Desai, Jayesh
Lau, Peter
Kansara, Maya
Simes, John
Thomas, David
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 9 October 2025
First Online: 21 November 2025
Competing interests
: D.T. as CEO of Omico, a non-profit organisation has received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene, Elevation Oncology, RedX Pharmaceuticals, Sun-Pharma, Bayer, Abbvie, George Clinical, Janssen, Merck, Kinnate, Microba, BioTessellate, Australian Unity, Foundation Medicine, Guardant, Intervenn, Amgen, Seattle Genetics and Eli Lilly. D.T. also serves on the advisory boards or committees for Canteen, UNSW SPHERE and NSW government in respect to genomics and translational medicine. The authors otherwise declare no competing financial or non-financial interests.
